Revista de neurologia
-
Revista de neurologia · Feb 2006
Review[Pregabalin: new therapeutic contributions of calcium channel alpha2delta protein ligands on epilepsy and neuropathic pain].
To review and update the contributions of a new class of drugs, named calcium channel alpha2delta protein ligands, on the treatment of epilepsy and neuropathic pain. ⋯ Pregabalin and calcium channel alpha2delta protein ligands showed relevant advances on epilepsy and neuropathic pain treatment. In peripheral neuropathic pain conditions, if the criteria for efficacy are based on both pain relief and quality of life measures, pregabalin/gabapentin are suggested as choice treatment.
-
Revista de neurologia · Feb 2006
Review[Techniques for the functional evaluation of neurodevelopmental disorders].
To review the evaluation of neuropsychological functions by using non-invasive functional neuroimaging methods. ⋯ With the findings from these studies it has become possible to establish a topographic correlation between the functions and the basic brain processes involved in each paradigm. A growing body of clinical evidence proves the value of using them (especially MEG) with cases of epilepsy, language, dyslexia, autism and attention deficit hyperactivity disorder.
-
Revista de neurologia · Jan 2006
Review[Oxcarbazepine in the treatment of epilepsy. A review and update].
To review and update the most important information concerning the mechanism of action, efficacy, safety and clinical use of oxcarbazepine (OXC), one of the new antiepileptic drugs (AED). ⋯ OXC showed important advances on safety and pharmacological properties for administration to adults and infants. OXC has similar clinical antiepileptic efficacy than older AED in the treatment of partial seizures, and it is recommended as a treatment of choice for partial seizures by several international guidelines.
-
Revista de neurologia · May 2005
Review[Clinical experiences with pregabalin in the treatment of focal epilepsies].
Pregabalin is an antiepileptic drug recently approved in the European Union for add-on therapy of focal epilepsy. A review of its clinical and pharmacological characteristics is, therefore, appropriate. ⋯ Pregabalin favourable pharmacokinetic profile, in addition to its good tolerability and remarkable efficacy make this new antiepileptic drug an attractive option for the treatment of focal epilepsies.
-
Revista de neurologia · Mar 2005
Review[Guidelines for the clinical management of neuropathic pain (II)].
Up to 5% of the population suffers from neuropathic pain (NP). A bibliographical search in several databases revealed that, to date, there are no protocols to guide physicians who are not specialists in pain that enable them to treat NP and thus improve patients' quality of life. ⋯ There is no specific set of guidelines for the treatment of NP. At the present time, the keystone of NP treatment consists in the use of antidepressant and anticonvulsive drugs. There is a need for further clinical trials to prove the effectiveness of using combined medication.